Maze Therapeutics (NASDAQ:MAZE) Insider Sells $210,150.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $28.02, for a total value of $210,150.00. Following the completion of the sale, the insider directly owned 26,250 shares in the company, valued at approximately $735,525. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, April 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $25.37, for a total value of $190,275.00.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE traded down $0.03 during trading hours on Wednesday, hitting $29.81. 1,090,902 shares of the company’s stock were exchanged, compared to its average volume of 718,935. The company’s 50-day moving average price is $25.75 and its 200-day moving average price is $35.80. Maze Therapeutics, Inc. has a 1-year low of $10.98 and a 1-year high of $53.65. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -11.78 and a beta of 2.26. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. On average, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on MAZE shares. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Wedbush raised their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. HC Wainwright boosted their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics in the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. boosted its holdings in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.